

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

**HIGHLY SPECIALISED TECHNOLOGY EVALUATION
PROGRAMME**

Equality impact assessment – Scoping

**HST elivaldogene autotemcel for treating cerebral
adrenoleukodystrophy**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Stakeholders noted that, if recommended, elivaldogene autotemcel:

- will help reduce health inequalities among people with rare diseases with regards to treatment accessibility in remote areas by being available to all UK patients
- will help reduce inequalities with mixed-race children who have difficulty to find a match for their stem cell transplantation

Other consultation comments indicated that there were no potential equality issues.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

The first issue does not relate to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Therefore, it was not seen as a potential inequality issue.

The second issue will be considered by committee in their decision-making where relevant.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name): Nicole Elliott

Date: 29/07/2021